Type I Diabetes Clinical Trial
Official title:
Measurement of Total Retinal Blood Flow in Patients With Diabetes and Healthy Subjects
Verified date | March 2017 |
Source | Medical University of Vienna |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The prevalence of diabetes and diabetes-associated complications is still increasing. Several major long-term complications of diabetes such as cardiovascular disease, chronic renal failure, diabetic retinopathy and others relate to the damage of blood vessels. Given that the eye provides the unique possibility in the human body to directly visualize blood vessels, much interest has been directed towards studying the ocular circulation. Although data of large epidemiological studies indicate that changes in retinal vessel caliber reflect other diabetes related factors, such as fasting glucose levels, there is still conflicting evidence on blood flow alterations in patients with diabetes. This is also related to the fact that up to now, methodological difficulties aggravate the assessment of blood flow changes in the retina in larger groups of patients. In the present study we propose to overcome this problem by using a technique called bi-directional Fourier Domain Doppler Optical Coherence Tomography (FDOCT), which we have developed in the recent years to measure retinal blood velocities. This technique allows for the non-invasive investigation of blood flow changes in human retina and will help us to better understand diabetes related vascular changes. The present study will use this technique to assess retinal blood flow changes in patients with diabetes and healthy subjects.
Status | Completed |
Enrollment | 48 |
Est. completion date | March 1, 2017 |
Est. primary completion date | August 26, 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Inclusion criteria for healthy subjects - Men and women aged over 18 years - Non-smokers - Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant - Normal ophthalmic findings, ametropia < 6 Dpt. Inclusion criteria for patients with diabetes - Men and women aged over 18 years - Non-smokers - Previously diagnosed type I diabetes - No or mild non-proliferative diabetic retinopathy - Normal ophthalmic findings except mild diabetic retinopathy, ametropia < 6 Dpt. Exclusion Criteria: Any of the following will exclude a healthy subject from the study: - Symptoms of a clinically relevant illness in the 3 weeks before the first study day - Presence or history of a severe medical condition as judged by the clinical investigator - Regular use of medication, abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study (except oral contraceptive) - Arterial hypertension (defined as either systolic blood pressure >145 mmHg or diastolic blood pressure >90 mmHg) - Blood donation during the previous three weeks - Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator - Best corrected visual acuity < 0.8 Snellen - Ametropia >= 6 Dpt - Pregnancy, planned pregnancy or lactating Any of the following will exclude a patient with diabetes from the study: - Participation in a clinical trial in the 3 weeks preceding the screening visit - Symptoms of a clinically relevant illness in the 3 weeks before the first study day - Presence or history of a severe medical condition, except diabetes, as judged by the clinical investigator - Arterial hypertension (defined as either systolic blood pressure >145 mmHg or diastolic blood pressure >90 mmHg) - Blood donation during the previous three weeks - Moderate to severe non-proliferative or proliferative diabetic retinopathy - Previous laser photocoagulation treatment - Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator - Best corrected visual acuity < 0.8 Snellen - Ametropia >= 6 Dpt - Pregnancy, planned pregnancy or lactating |
Country | Name | City | State |
---|---|---|---|
Austria | Department of Clinical Pharmacology | Vienna |
Lead Sponsor | Collaborator |
---|---|
Medical University of Vienna |
Austria,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Total retinal blood flow | Measurement of total retinal blood flow using the Dynamic Vessel Analyzer and Optical Coherence Tomography | 1 day | |
Secondary | Retinal vessel diameter | Measurement of retinal vessel diameter using the Dynamic Vessel Analyzer | 1 day | |
Secondary | Retinal blood velocities | Measurement of retinal blood flow velocities using Fourier Domain Optical Coherence Tomography | 1 day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05160142 -
Diabetes Inspired Culinary Education
|
Early Phase 1 | |
Withdrawn |
NCT05035368 -
Ladarixin as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Type 1 Diabetes
|
Phase 2 | |
Completed |
NCT01928329 -
A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes
|
Phase 2 | |
Completed |
NCT02127762 -
The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy
|
N/A | |
Completed |
NCT00999375 -
Cultivating Healthy Environments in Families With Type 1 Diabetes (CHEF)
|
Phase 2 | |
Completed |
NCT04279613 -
A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041
|
Phase 1 | |
Not yet recruiting |
NCT02117518 -
Selective Immunotargeting of Pathogenic CD8 T Cells of Type 1 Diabetes Patients
|
N/A | |
Withdrawn |
NCT01477476 -
Anti-IL-1 Treatment in Children Diabetic Keto-Acidosis (DKA) at Diagnosis of Type 1 Diabetes
|
Phase 2 | |
Terminated |
NCT01308437 -
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
|
Phase 3 | |
Terminated |
NCT01652911 -
A Phase I/II Study of the Safety and Efficacy of Sernova's Cell PouchTM for Therapeutic Islet Transplantation
|
Phase 1/Phase 2 | |
Completed |
NCT06242548 -
How Type I Diabetes Responds to Different Diets (Normoglucidic or Ketogenic) During Physical Activity at Altitude
|
N/A | |
Completed |
NCT00351650 -
Assessment of Beta Cell Mass in Type 1 Diabetes With 11C-Dihydrotetrabenazine and PET Scan
|
N/A | |
Withdrawn |
NCT00361608 -
Monitoring of Nocturnal Hypoglycemia Using EarlySense Monitoring Device
|
N/A | |
Terminated |
NCT03653533 -
Evaluation of the Function "Stop Before Hypoglycemia" on External Insulin Pump
|
N/A | |
Completed |
NCT00340639 -
Management of Type 1 Diabetes Among Adolescents
|
N/A | |
Completed |
NCT02002130 -
The Use of Glutamic Acid Decarboxylase (GAD) and Gamma-Amino Butyric Acid (GABA) in the Treatment of Type I Diabetes
|
Phase 1 | |
Completed |
NCT02634216 -
Effects of Capros in Patients With Type-1 Diabetes
|
N/A | |
Withdrawn |
NCT01623388 -
Epigenetic Modifications of Diabetes Mellitus Type I
|
N/A | |
Completed |
NCT02612493 -
Obesity and Metabolic Surgery in Patients With Type I Diabetes
|
N/A | |
Withdrawn |
NCT01398670 -
Immunogenicity Study of Wockhardt's Insulin Lispro/Lispro Mix Basal Bolus Regimen in Type 1 Diabetics
|
Phase 3 |